ReviewParasites & vectors2014
Research progress on surface antigen 1 (SAG1) of Toxoplasma gondii.
Review in Parasites & vectors, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 89 citations in OpenAlex.
- Zoonotic Parasite Nanovaccines: Progress, Challenges, and Future Perspectives.Integrative zoology · 2026Review
- Evaluation of recombinant TgGRA14 as a diagnostic antigen for detection of Toxoplasma gondii antibodies in cattle.BMC veterinary research · 2026Article
- Development of a SAG1-based colloidal gold immunochromatographic strip for rapid serological detection of swine Toxoplasma gondii.Parasites & vectors · 2026Article
- Article
- Purification and Characterization of Immunoglobulin Y (IgY) Targeting Surface Antigen 1 (SAG1) ofAntibodies (Basel, Switzerland) · 2025Article
- Design of a Multi-epitope Antigen for Toxoplasmosis Diagnosis: An Immunoinformatics Approach.Acta parasitologica · 2025Article
- Design and immunological evaluation of a multi-epitope vaccine candidate againstFood and waterborne parasitology · 2025Article
- Surface antigen SAG1 mediatesInfection and immunity · 2025Article
- Novel antibodies detect nucleocytoplasmic O-fucose in protist pathogens, cellular slime molds, and plants.mSphere · 2025Article
- Antibody Responses to EBV and Toxoplasma and Their Genetic Links to Guillain-Barré Syndrome: A Mendelian Randomization Study.Brain and behavior · 2025Article
- Characterization of the immune response to recombinant GRA-4 protein (rGRA-4) ofOpen veterinary journal · 2025Article
- Specific Cell Targeting byCells · 2024Article
- Recombinant production of SAG1 fused with xylanase in Pichia pastoris induced higher protective immunity against Eimeria tenella infection in chicken.Microbial biotechnology · 2024Article
- Stable expression of mucin glycoproteins GP40 and GP15 of Cryptosporidium parvum in Toxoplasma gondii.Parasites & vectors · 2024Article
- Toxoplasma gondii vaccine candidates: a concise review.Irish journal of medical science · 2023Review
- scDual-Seq ofFrontiers in immunology · 2023Article
- PLGA Nanoparticles as an Efficient Platform in Protein Vaccines Against Toxoplasma gondii.Acta parasitologica · 2022Review
- Mining the Proteome ofAnimals : an open access journal from MDPI · 2022Review
- A Novel Combined DNA Vaccine Encoding Toxoplasma gondii SAG1 and ROP18 Provokes Protective Immunity Against a Lethal Challenge in Mice.Acta parasitologica · 2021Article
- Descriptive Comparison of ELISAs for the Detection ofPathogens (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toxoplasma gondii is an obligate intracellular parasitic protozoan that has a wide host range and causes a zoonotic parasitosis called toxoplasmosis. This infection causes significant morbidity, costs for care and loss of productivity and suffering. The most effective measures to minimize this parasite's harm to patients are prompt diagnosis and treatment and preventing infection. A parasite surface antigen, SAG1, is considered an important antigen for the development of effective diagnostic tests or subunit vaccines. This review covers several aspects of this antigen, including its gene structure, contribution to host invasion, mechanisms of the immune responses and its applications for diagnosis and vaccine development. This significant progress on this antigen provides foundations for further development of more effective and precise approaches to diagnose toxoplasmosis in the clinic, and also have important implications for exploring novel measures to control toxoplasmosis in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.